Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Biomedical Engineering
SJR: 0.207 SNIP: 0.376 CiteScore™: 0.79

ISSN Druckformat: 0278-940X
ISSN Online: 1943-619X

Volumes:
Volumen 47, 2019 Volumen 46, 2018 Volumen 45, 2017 Volumen 44, 2016 Volumen 43, 2015 Volumen 42, 2014 Volumen 41, 2013 Volumen 40, 2012 Volumen 39, 2011 Volumen 38, 2010 Volumen 37, 2009 Volumen 36, 2008 Volumen 35, 2007 Volumen 34, 2006 Volumen 33, 2005 Volumen 32, 2004 Volumen 31, 2003 Volumen 30, 2002 Volumen 29, 2001 Volumen 28, 2000 Volumen 27, 1999 Volumen 26, 1998 Volumen 25, 1997 Volumen 24, 1996 Volumen 23, 1995

Critical Reviews™ in Biomedical Engineering

DOI: 10.1615/CritRevBiomedEng.2014011578
pages 193-212

Drug-Coated Percutaneous Balloon Catheters

Jayesh V. Betala
Department of Bioengineering, Clemson University, Clemson, South Carolina
Eugene M. Langan III
Department of Vascular Surgery, Greenville Health System, Greenville, South Carolina
jayesh betala
Clemson University

ABSTRAKT

Percutaneous transluminal angioplasty revolutionized coronary and peripheral revascularization. However, it is always accompanied by major drawbacks such as elastic recoil and neointimal hyperplasia. Percutaneous transluminal angioplasty along with bare metal stents reduced elastic recoil, but in-stent restenosis (ISR) and peripheral artery stenting remain problems. Drug-eluting stents addressed the issue of ISR, but late stent thrombosis and delayed endothelialization, along with longer dual antiplatelet therapy, are of concern. Non-stent-based delivery such as drug-coated balloons (DCBs) that can deliver drugs to inhibit ISR or to de novo lesions, are emerging at a rapid pace. DCBs carry an active drug and a nonpolymeric carrier molecule or excipient that enhance the bioavailability of the drug to the vessel wall. Preliminary studies of paclitaxel show sustained delivery is not required to inhibit proliferation of vascular smooth muscle cells, which leds to the development and evolution of DCBs. Recent clinical trials have been successful in mitigating ISR in coronary and peripheral arteries, but not in de novo lesions of coronary arteries. Clinical studies, although limited to date, show a promising future for DCBs.